anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, particularly, parapharmaceutical industry producing preparations of treating and prophylactic action; applicable as auxiliary anesthetic agent. SUBSTANCE: biologically active additive contains cinnamon, clove, nutmeg, balm, and lemon. Besides, it contains infusions of peppermint and valerian, camomile, ginger. Biologically active additive may be prepared in the form of cryopowders, tablets, infusions, syrups, extracts. Proposed preparation arrests headache, pain in region of heart, in stomach and intestine. Preparation may be used when spasms, neuralgia, rheumatism, and algomenorrhea. EFFECT: higher efficiency. 2 cl, 1 tbl, 3 n
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, and concerns compositions and methods for treating severe acute respiratory syndrome (SARS). Substance of the invention includes a pharmaceutical composition for treating severe acute respiratory syndrome SARS, containing a therapeutically effective amount of recombinant TNF- receptor or thalidomide in a pharmaceutically acceptable carrier. Also, presented is a method of treating SARS with using this composition, as well as a method of preparing the composition. ^ EFFECT: drug for treating SARS is developed. ^ 43 cl, 2 ex
The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes). For control ,none of the intervention will be given.
Participants undergoing resection for a presumed newly-diagnosed glioblastoma (WHO grade 4) will be treated with niraparib for 4 days prior to surgical resection. Participants who proceed to the therapeutic expansion phase of this study will receive niraparib in combination with radiation (60 Gy over 6-7 weeks, as per standard of care). Following radiotherapy, eligible study participants may receive niraparib maintenance treatment.
OBJECTIVE: Impaired QoL and depression are common in patients with chronic epilepsies; however, data on the impact of a first seizure on QoL are sparse. According to the current ILAE-definition of epilepsy, patients may be diagnosed with epilepsy immediately after the first seizure, if EEG and/or imaging findings are abnormal. Patients with normal findings in imaging and EEG are not diagnosed as having epilepsy. We investigated QoL in patients after a first seizure with and without a consecutive diagnosis of epilepsy to detect differences between groups within the first year after seizure.
METHODS: We examined patients (n = 152) after a first epileptic seizure and six and 12 months thereafter using demographic, clinical and QoL-related questionnaire data (Short Form-36 Health Survey (SF-36), Quality of Life in Epilepsy Inventory-31 (QOLIE-31), Beck's depression inventory II (BDI-II)).
RESULTS: Patients diagnosed with epilepsy after the first seizure showed a tendency of reduced mental health-related QoL six (p =.098) and 12 months (p =.092) after the first seizure compared to patients who were not diagnosed with epilepsy, but were diagnosed as having had a single first seizure. There were no significant differences between the two groups in physical health-related QoL. Multiple regression analyses showed that especially depressive symptoms explained 22.0 - 48.7 % of the variance in mental health-related QoL six (p <.001) and 12 months (p <.001) after the first seizure. Physical health-related QoL was especially predicted by age (p <.001), group (p =.002) and recurrent seizures (p = < 0.001). In PWE, there was a statistical trend with improving QOLIE-31 overall scores from six to 12 months (p =.086).
CONCLUSION: Our results suggest that QoL may be impaired in patients diagnosed with epilepsy early, immediately after the onset of disease. Early follow-up monitoring from the beginning of patient career is important for possible interventions and to improve patients' daily life in the long term.
BACKGROUND: A preoperative, in-community antimicrobial decolonization protocol combining chlorohexidine gluconate (CHG) sponges and mupirocin ointment to reduce surgical site infections amongst hip and knee replacement patients has been adopted in Alberta, Canada. Patient compliance with the protocol is essential for effectiveness. It is, therefore, important to understand patterns, and reasons why, patients do, and do not, comply.
METHODS: A descriptive survey of patients having elective total hip or knee replacement at seven clinics in Alberta was conducted to determine patient compliance and reasons for noncompliance. Descriptive statistics and multivariate logistic regression were computed.
RESULTS: Patient compliance was assessed in 3,427 patients. There were no differences in compliance based on the baseline protocols and enhanced protocols, but there was a difference based on clinic location. The odds of compliance with three CHG sponges were 4.47 times higher in rural versus urban clinics (P < .001). The most common reason for noncompliance for patients instructed to use 3 CHG sponges was "patient forgot".
CONCLUSIONS: Compliance did not change when enhanced protocols were introduced; however, compliance differed by clinic location. Reasons for noncompliance included "sponges not provided", "patient forgot", and "surgery date moved". Results may inform clinics on areas where improvements could be made to increase patient compliance.
PROBLEM TO BE SOLVED: To enhance UV shielding function, etc., by irregularly piling up primary flaky silica particles to form silica aggregate particles with gaps and carrying fine metal oxide particles on the surfaces of the silica aggregate particles and on the inner surfaces of the gaps. SOLUTION: Fine metal oxide particles are preferably fine particles of one or more selected from titanium dioxide, zinc oxide, cerium oxide, iron oxide and zirconium oxide. The primary particle size of the fine particles is preferably 0.002-0.5 μm m. The amt. of the fine metal oxide particles in the objective composite is preferably 1-80 wt.%. When titanium dioxide and zinc oxide are mixed and used for shielding UV, the amt. of titanium dioxide is preferably 10-60 wt.% of the total amt. The thickness of the primary flaky silica particles is preferably 0.001-1 μm and the ratio of the max. length of the flakes to the thickness (aspect ratio) is preferably at least 10.
NEW MATERIAL:A glycoprotein JI-36, derived from cancerous cell membrane components and having the following properties. Having the structure expressed by a formulas I and II. Sugar protein ratio [(neutral sugar content + amino- sugar content)/protein content] obtained from the neutral sugar content mea sured by the phenol-sulfuric acid method, amino-sugar content obtained by Elson-Morgan method and protein content obtained by the Lawry method; 1.3+ or -0.3. Constituent sugar; Gal and GlcNAc as principal ingredients and containing Fuc, Man, GalNAc and Sia. Ultraviolet spectrum; maximum absorp tion at 270-280nm USE:An anticancer and antirheumatic agents. PREPARATION:For example, a human gastric cell is homogenized in ice water and ultracentrifuged to separate a supernatant, which is then subjected to gel filtration to collect a protein fraction. A 2.5 M tris hydrochloric acid buffer solution is subsequently added thereto to carry out ultrasonic treatment. Dithiothreitol and iodoacetamide are successively added thereto. After treatment, gel filtration is performed and the filtrate is dialyzed to afford the glycoprotein JI-36.
1. An aqueous suspension for nasal administration which comprises loteprednol etabonate and microcrystalline cellulose carmellose sodium. 2. The aqueous suspension for nasal administration according to Claim 1, which contains 0.05-3 w/w % of loteprednol etabonate and 0.5-10 w/w % of microcrystalline cellulose carmellose sodium. 3. The aqueous suspension for nasal administration according to Claim 1, which contains 0.1-1.5 w/w % of loteprednol etabonate and 1-5 w/w % of microcrystalline cellulose carmellose sodium. 4. A method of treating inflammation or allergy which comprises administering an effective amount of the aqueous suspension for nasal administration comprising loteprednol etabonate and microcryatalline cellulose carmellose sodium to nasal mucosa. 5. The method according to Claim 4, wherein the aqueous suspension for nasal administration comprises 0.05-3 w/w% of loteprednol etabonate and 0.5-10 w/w % of microcrystalline cellulose carmellose sodium.
The brain bidirectionally communicates with the gut to control food intake and energy balance, which becomes dysregulated in obesity. For example, endocannabinoid (eCB) signaling in the small-intestinal (SI) epithelium is upregulated in diet-induced obese (DIO) mice and promotes overeating by a mechanism that includes inhibiting gut-brain satiation signaling. Upstream neural and molecular mechanism(s) involved in overproduction of orexigenic gut eCBs in DIO, however, are unknown. We tested the hypothesis that overactive parasympathetic signaling at the muscarinic acetylcholine receptors (mAChRs) in the SI increases biosynthesis of the eCB, 2-arachidonoyl-sn-glycerol (2-AG), which drives hyperphagia via local CB1Rs in DIO. Male mice were maintained on a high-fat/high-sucrose Western-style diet for 60 d, then administered several mAChR antagonists 30 min prior to tissue harvest or a food intake test. Levels of 2-AG and the activity of its metabolic enzymes in the SI were quantitated. DIO mice, when compared to those fed a low-fat/no-sucrose diet, displayed increased expression of cFos protein in the dorsal motor nucleus of the vagus, which suggests an increased activity of efferent cholinergic neurotransmission. These mice exhibited elevated levels of 2-AG biosynthesis in the SI, that was reduced to control levels by mAChR antagonists. Moreover, the peripherally restricted mAChR antagonist, methylhomatropine bromide, and the peripherally restricted CB1R antagonist, AM6545, reduced food intake in DIO mice for up to 24 h but had no effect in mice conditionally deficient in SI CB1Rs. These results suggest that hyperactivity at mAChRs in the periphery increases formation of 2-AG in the SI and activates local CB1Rs, which drives hyperphagia in DIO.
This study is being done to answer the following question: Can creating 3D models using tumour samples and looking at genetic information from pancreatic ductal adenocarcinoma (PDAC) tumours, help us to provide more patients with a specific, personalized treatment? Two groups of patients with PDAC are eligible to enroll 1) PDAC patients that will go straight to surgery 2) PDAC patients where the disease is either too advanced for a surgical option, or the disease has spread to other areas in the body. Patients will have tumour tissue taken either during their surgery or from a biopsy at enrolment. Background history, outcome data, questionnaires, series of blood draws and stool samples will be collected for analyses. All electronic medical record information will also be collected.

Researchers are looking for better ways of understanding and treating pancreatic cancer by looking to see how useful it is to know about changes and characteristics in the genes in the tumour (molecules that contain instructions for the development and functioning of the cells). Results from analyzed data may be useful in choosing treatments for enrolled patients and for patients in the future. Patients current treatment plan will not change if they choose to take part in this study.
In one aspect, a cosmetic composition includes a sunless tanning agent and a sunscreen agent. A photostabilizer is added to stabilize the sunscreen agent from the destabilizing effect of the sunless tanning agent. In this manner, UV protection is provided to the user when the cosmetic composition is applied to skin. In another aspect, a water-based sunless tanning/sunscreen composition includes a sunless tanning agent, a sunscreen agent, and a photostabilizer. The sunless tanning agent is DHA, and the sunscreen is avobenzone. Because the avobenzone degrades when exposed to UV  radiation when used with DHA, the photostabilizer is added to enable the avobenzone to retain most of its original ability to absorb the UV radiation. The photostabilizer is a low molecular weight copolymer of adipic acid and neopentyl glycol.
BACKGROUND & AIMS: Non-selective β blockers (NSBBs) may negatively influence renal function through decreasing heart rate and cardiac output. This study aimed to systematically investigate their association.
METHODS: PubMed, EMBASE, and Cochrane library databases were searched to identify all relevant studies evaluating the association of NSBBs with renal dysfunction in cirrhotic patients. Unadjusted and adjusted data were separately extracted. Odds ratios (ORs) and hazard ratios (HRs) were pooled. Subgroup meta-analyses were performed according to the proportions of ascites and Child-Pugh class B/C and the mean model for end-stage liver disease (MELD) score. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework.
RESULTS: Fourteen studies were finally included. Based on unadjusted data, NSBBs significantly increased the risk of developing renal dysfunction (OR = 1.49; p = 0.03), and this association remained significant in subgroup analyses of studies where the proportions of ascites was >70% and Child-Pugh class B/C was 100%. Based on adjusted data with propensity score matching (adjusted OR = 0.61; p = 0.08) and multivariable regression modelling (adjusted HR = 0.86; p = 0.713), NSBBs did not increase the risk of developing renal dysfunction, and this association remained not significant in subgroup analyses of studies where the proportions of ascites was >70% and <70%, the proportion of Child-Pugh class B/C was <100%, and the mean MELD score was <15. The quality of evidence was very low for all meta-analyses.
CONCLUSIONS: NSBBs may not be associated with the development of renal dysfunction in liver cirrhosis. However, more evidence is required to clarify their association in specific populations.
The present invention relates to a production method for savoury chicken cooked in a semiautomatic mode, which comprises the processes of cleaning, regulation, heating in water, steeping, drying, refrigeration and packing and especially comprises the technologies of preliminary constant temperature, secondary steeping, refrigeration and taste addition. A pulled chicken is soaked in a preheating pool with the constant temperature of 30 DEG C, and then, the pulled chicken is hung in a steeping pool with the temperature of 95 DEG C. Spices of a prescription A are added to the pulled chicken for carrying out steeping, and then, the pulled chicken is dipped in a steeping pool with the temperature of 85 DEG C. After being cooked, the pulled chicken is put in an ice water pool for being hastily frozen, and spices of a prescription B are added for carrying out the taste addition of the pulled chicken. Hot water in the steeping pool is provided by a high position constant temperature pool so as to ensure that the temperature of hot water is controllable and stable, and the hot water is circularly used for reducing energy consumption. The temperature of the hot water is automatically controlled by a temperature control meter and an electromagnetic valve. The quality of finished products is ensured, meat quality is fresh, delicious, tender, smooth and flavorful, production environment is sanitary and safe, and industrialization production is realized. The present invention is suitable for replacing the existing workshop type production method for steeping meat chickens.
BACKGROUND: Aging beyond 65 years is associated with increased prevalence of urinary incontinence (UI), frailty, and increased complication rate with UI treatments. To investigate this relationship, we examined frailty as a predictor of procedure-based UI treatment patterns and urologic complications in Medicare-eligible women.
METHODS: We identified women undergoing procedures for UI between 2011 and 2018 in the 5% limited Medicare data set. A claims-based frailty index (CFI) using data from the 12 months prior to the index procedure defined frailty (CFI ≥0.25). Urologic complications were assessed during the 12 months following the index procedure. We used unadjusted logistic regression models to calculate odds of having a specific type of UI procedure based on frailty status. Odds of postprocedure urologic complications were examined with logistic regression adjusted for age and race.
RESULTS: We identified 21 783 women who underwent a procedure-based intervention for UI, of whom 3 826 (17.5%) were frail. Frail women with stress UI were 2.6 times more likely to receive periurethral bulking (95% confidence interval [CI] 2.26-2.95), compared to nonfrail. Conversely, frailty was associated with lower odds of receiving a Sling or Burch colposuspension. Among women with urgency UI or overactive bladder, compared to nonfrail, frailty was associated with higher odds of both sacral neuromodulation (odds ratio [OR] = 1.21, 95% CI: 1.11-1.33) and intravesical Botox (OR = 1.16, 95% CI: 1.06-1.28), but lower odds of receiving posterior tibial nerve stimulation. Frailty was associated with higher odds of postprocedure urologic complications (OR = 1.64, 95% CI: 1.47-1.81).
CONCLUSIONS: Frailty status may influence treatment choice for treatment of stress or urgency UI symptoms and increase the odds of postprocedural complications in older women.
PROBLEM TO BE SOLVED: To obtain the subject medicine which can be percutanously absorbed by formulating an antiinflamatory antipyretic analgesic of oxicams with a herb medicinal ingredient [enhancer]. SOLUTION: This medicine contains 0.1-50wt.% of an antiinflammatory antipyretic analgesic of oxicams, 0.1-70wt.% of a herb medicinal ingredient [enhancer] and a necessary percutanous absorption vehicle. As the antiinflammatory antipyretic analgesic of oxicams, isoxicam, pyroxicam and cinnoxicam are exemplified and as the herb medicinal ingredient [enhancer], oleanolic acid, trans-cinnamic acid, glycyrrhizin, β-myrcene and terpineol are illustrated. Further, the vehicle contains ethylene glycol or sodium carbomethoxymethyl cellulose in an amount of 0.01-99.95wt.%. This medicine can be pharmaceutically manufactured in forms of ointment, emulsion, gel, solution, spray and paste.  In the percutaneous drug delivery system containing an antiinflammatory agent, oxicam, as the major medicine, addition of the herb medicinal ingredient [enhancer] affords high effect of enhancing percutaneous absorption.
The invention comprises a viral cap-leader sequence which comprises at least three bases complementary to the 3′-ultimate residues of a (−)ssRNA virus template sequence. Preferably said consensus sequence is represented by the general formula  7m G(N) 6-10- (A/U/G)−A/U−AGC, more preferably  7m G(N) 7-8- (A/U/G)−A/U−AGC. Further comprised are modified cap-leader sequences that are able to block elongation by the viral polymerase or cleavage by the viral endonuclase. Such modified cap-leader sequences comprise a 3′-terminal phosphate group, one or more phosphorothioate or phosphorodiamidate bonds or one ore more morpholino rings. Also pharmaceutical products comprising such a modified cap-leader sequence are disclosed. Further, the invention comprises methods for inhibiting virus transcription, especially for influenza virus, using such a modified cap-leader sequence or pharmaceutical product.
OBJECTIVE: To compare the health impact and economic benefits among individuals who did not receive the human papillomavirus (HPV) vaccine to those who received a single dose, or 2 doses. The comparison was stratified by 4 types of vaccine in conjunction with primary HPV screening in a low/middle-income country setting.
METHODS: A Markov model was employed to simulate HPV infection and cervical cancer in a cohort of 100,000 12-year-old girls free of HPV. The study scrutinized 9 strategies: 1 dose and 2 doses of 2vHPV (Cervarix®), 2vHPV (Cecolin®), 4vHPV (Gardasil®), 9vHPV vaccine (Gardasil9®), and no vaccination. The primary outcome measure was the quality-adjusted life year (QALY) of each strategy. Incremental cost-effectiveness ratios were estimated over a lifetime horizon, accompanied by sensitivity analyses conducted.
RESULTS: All vaccination programs yielded 41,298-71,057 QALYs gained accompanied by cost savings of 14,914,186-19,821,655 USD compared to no vaccination. Administering 2 doses of 9vHPV vaccine emerged as the most cost-effective strategy, boasting 406 USD/QALY, within a lower willingness to pay threshold. Sensitivity analysis demonstrated an 80% probability of the cost-effectiveness of the 2 doses of 9vHPV vaccine regimen. Furthermore, uncertainty around the costs of vaccination and vaccine efficacy exerted the most substantial influence on the cost-effectiveness findings.
CONCLUSION: Oping for 2 doses of 9vHPV vaccine in conjunction with a primary HPV screening represents the most cost-effective option for implementing a school-based HPV vaccination program targeting 12-year-old girls in Thailand. Such findings provide valuable insights for policymakers in the realm of cervical cancer prevention.
PROBLEM TO BE SOLVED: To provide a soap contg. a plant extract which can provide effects of making bare skin clear and beautiful and effects of improving blood circulation. SOLUTION: This soap contains at least one plant extract obtd. from a plant of the genus Calanthe discolor Lindl. or Phaiusflavus Lindl. of the family Orchidaceae. For example, the plant extract it collected by water washing and finely cutting a calanthe, immersing and extracting 300 g of the cut calanthe in and with 1,000 cc of an aq. 70% alcohol soln., and filtering the slon. By using a soap contg. 20 wt.% extract powder obtd. as above for 3 months, anitpruritic effects against atopy are obtd. in addition to effects of making bare skin clear and beautiful and the effects of improving blood circulation, and the gloss and tension of skin are improved.
BACKGROUND Emergence agitation, or delirium, occurs during early recovery from general anesthesia and involves disorientation, excitation, and uncontrolled physical movements. Dexmedetomidine is an alpha agonist that has sedative, anxiolytic, analgesic, and sympatholytic activities and is used as a continuous infusion to prevent emergence agitation. This study aimed to evaluate patients aged 65 years and older undergoing general anesthesia to determine the 90% effective dose (ED90) of dexmedetomidine continuous intraoperative infusion to prevent emergence agitation. MATERIAL AND METHODS We enrolled 44 patients aged 65 years and older undergoing spinal surgery under general anesthesia. Dexmedetomidine administration commenced 30 minutes before surgery completion, with a predetermined infusion dose (μg/kg/h), without a loading dose. The initial dose was 0.2 μg/kg/h, and subsequent step size was ±0.05 μg/kg/h. We tried to find ED90 of dexmedetomidine using the biased-coin design. Vital signs, extubation quality scores, extubation-related complications, and postoperative outcomes were monitored. RESULTS Dexmedetomidine ED₉₀ for smooth emergence in older patients was 0.34 μg/kg/h. Peri-extubation vital signs remained within 20% of baseline values, without requiring pharmacological intervention. No hypoxia, hypoventilation, or post-extubation agitation occurred. In the recovery room, 1 patient briefly exhibited excitement but quickly calmed. Nine patients initially unresponsive in the recovery room fully awoke and were promptly discharged. CONCLUSIONS For older patients who are vulnerable to adverse effects of anesthetics and opioids, dexmedetomidine enables gentle awakening without adverse vital sign changes, respiratory depression, excessive sedation, or emergence agitation (ED₉₀=0.34 μg/kg/h). Further studies should involve a larger patient cohort, considering diverse medical conditions in older individuals.